Kalofonos Isabel 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jan 7, 2026
Insider Transaction Report
Form 4
Kalofonos Isabel
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-05$40.59/sh+2,500$101,475→ 3,334 total - Sale
Common Stock
2026-01-05$55.00/sh−2,500$137,500→ 834 total - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-05−2,500→ 97,500 totalExercise: $40.59Exp: 2035-01-10→ Common Stock (2,500 underlying)
Footnotes (4)
- [F1]Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan.
- [F2]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2025.
- [F3]The common stock was sold by the Reporting Person in an open market transaction on the transaction date, at a sale price of $55.00 per share.
- [F4]The option is exercisable as follows: 25% of the shares subject to the option vested on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.